Progress in human tumour immunology and immunotherapy

Steven A. Rosenberg

Research output: Contribution to journalReview article

Abstract

Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney cancer have shown that immunological manipulations can mediate the durable regression of metastatic cancer. The molecular identification of cancer antigens has opened new possibilities for the development of effective immunotherapies for patients with cancer. Clinical studies using immunization with peptides derived from cancer antigens have shown that high levels of lymphocytes with anti-tumour activity can he raised in cancer-bearing patients. Highly avid anti-tumour lymphocytes can be isolated from immunized patients and grown in vitro for use in cell-transfer therapies. Current studies are aimed at understanding the mechanisms that enable the cancer to escape from immune attack.

Original languageEnglish (US)
Pages (from-to)380-384
Number of pages5
JournalNature
Volume411
Issue number6835
DOIs
StatePublished - May 17 2001

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Progress in human tumour immunology and immunotherapy'. Together they form a unique fingerprint.

  • Cite this